ABT-957
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
0
Sites
13
Countries
1
Endpoints
4
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 4 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 4 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT02573740Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment | ABT-957 Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD | Ph 1 | Terminated | 9 | Jun 2016 | 1 | |
| NCT02220738Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors | ABT-957 Alzheimer’s disease | mild-to-moderate AD | Ph 1 | Terminated | 4 | Mar 2016 | 1 |
Showing 1-2 of 2 trials